Dr Reddy’s Debuts Two Revlimid Exclusives As Part Of Complete Launch In US

End Of Teva Exclusivity Period Opens Door For Several Lenalidomide ANDA Approvals

Dr Reddy’s Laboratories is set to reap the rewards of a significant US generic launch – albeit one with a limited volume caveat decreed by a patent-litigation settlement deal – after it began selling its generic of Bristol Myers Squibb’s multi-billion-dollar blockbuster Revlimid.

Launches Neon Sign Brick Wall
Dr Reddy’s has launched multiple presentations of lenalidomide, two with exclusivity • Source: christitzeimaging.com / Alamy Stock Photo

Dr Reddy’s has realized plans to introduce the two strengths of its generic version of Bristol Myers Squibb’s multi-billion-dollar blockbuster Revlimid (lenalidomide) in the US for which it holds 180-day generic exclusivity, as part of a complete six-strength offering.

The Indian firm’s launch, including lenalidomide 2.5mg and 20mg capsules with an exclusivity period, came as a glut of other...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Products

Kashiv’s Xolair Biosimilar Nears US And EU Filings As Phase III Data Reports

 

Following the filing acceptance in the UK earlier this year, Kashiv and its three commercial musketeers – Alvotech, Advanz Pharma, and Amneal – are getting ready for applications in the US and Europe.

Repurposed Drugs: EU Pharma Reform Offers Boost, But Payers ‘Must Recognize Health Gains’

 

Incentives for repurposed drugs proposed as part of the EU pharma reform package are a “great step forward,” but more recognition is needed from payers and regulators to leverage the benefits of these medicines, experts say.

Formycon Signs US-Canada Deal With Valorum Biologics For Eylea Biosimilar

 

Formycon continues to expand its partnership network with a fresh deal for its aflibercept biosimilar in the US and Canada. At the same time, the firm has received a high demand for its corporate bonds, leading to early offering closure.

Bio-Thera And SteinCares Add Mega-Blockbuster Dupilumab To Latin America Alliance

 
• By 

Bio-Thera Solutions is back with its third agreement with Costa Rica-based SteinCares for the supply of a biosimilar in Latin America – this time for the Chinese firm’s proposed rival to Sanofi and Regeneron’s Dupixent (dupilumab)

More from Generics Bulletin

Zentiva Strikes Deal With Aboca To Expand CHC Offering

 
• By 

Czech Republic's Zentiva snaps up Aboca portfolio adding supplement brands marketed in European countries such France, Italy and Spain.

Will Amarin Finally Launch An Authorized Generic Version Of Vascepa?

 
• By 

As it offloads commercial rights to the brand in Europe, Amarin has for the umpteenth time teased the possibility of launching an authorized generic version of Vascepa in the US.

Bio-Thera And SteinCares Add Mega-Blockbuster Dupilumab To Latin America Alliance

 
• By 

Bio-Thera Solutions is back with its third agreement with Costa Rica-based SteinCares for the supply of a biosimilar in Latin America – this time for the Chinese firm’s proposed rival to Sanofi and Regeneron’s Dupixent (dupilumab)